Marc Rovner, MD
Pulmonary Disease · Lima, OHNPI 1093795668
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $53,345 of the $70,611 with a category attached, or 75.5%. AstraZeneca accounts for 87.2% of it on its own, with 20 other manufacturers making up the rest. Among pulmonary disease clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 165 payments — averaging $427.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$62K
- Amgen$6K
- GSK$762
- Regeneron Healthcare Solutions, Inc.$510
- Astrazeneca UK Limited$465
- Sanofi$235
- plus $1K from 15 others
Across 7 payments — averaging $8022.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$30K
- Roche Products Limited$26K
What the payments were for
- Consulting fees$5,3488%
- Speaking & faculty fees$53,34576%
- Travel & lodging$5,8268%
- Food & beverage$5,8758%
- Education$2170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 89 | $61,560 |
| Amgen | 9 | $5,981 |
| GSK | 13 | $762 |
| Regeneron Healthcare Solutions, Inc. | 14 | $510 |
| Astrazeneca UK Limited | 1 | $465 |
| Sanofi | 5 | $235 |
| Pulmonx Corporation | 1 | $145 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $126 |
| Johnson & Johnson | 1 | $124 |
| Mylan Specialty L.p. | 6 | $99 |
| Insmed, Inc. | 5 | $95 |
| Boehringer Ingelheim | 1 | $93 |
| Sanofi-aventis U.S. LLC | 1 | $79 |
| Viatris Specialty LLC | 4 | $75 |
| Verona Pharma, Inc. | 3 | $74 |
| Vifor Pharma, Inc. | 2 | $50 |
| Genentech USA, Inc. | 1 | $48 |
| Vapotherm Inc | 1 | $32 |
| Novartis | 1 | $22 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $22 |
| Covidien LP | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEZSPIRE$63,086
- FASENRA$374
- DUPIXENT$373
- BREZTRI$238
- NUCALA$234
- CHARTIS CATHETER$145
- ZEPHYR DELIVERY CATHETER$145
- ZEPHYR ENDOBRONCHIAL VALVE$145
- PULMONX CHARTIS TABLET CONSOLE$145
- AREXVY$125
- NA$124
- TRELEGY ELLIPTA$110
How this compares
$70,611 in reported general payments places this provider in the 95th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 698 | $620,563 |
| OfevNintedanib Esylate | 13 | $191,307 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 235 | $149,429 |
| Breo ElliptaFluticasone/Vilanterol | 219 | $116,720 |
| XolairOmalizumab | 30 | $103,872 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 116 | $91,718 |
| TezspireTezepelumab-Ekko | 17 | $77,288 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 90 | $63,302 |
| Dupixent PenDupilumab | 14 | $54,842 |
| NucalaMepolizumab | 13 | $50,011 |
| Spiriva RespimatTiotropium Bromide | 32 | $28,966 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 41 | $19,841 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 649 | $19,723 |
| Arnuity ElliptaFluticasone Furoate | 40 | $15,707 |
| SymbicortBudesonide/Formoterol Fumarate | 50 | $15,190 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Nucala, Arnuity Ellipta | $762 | $964,5821,222 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $93 | $283,575135 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Bevespi Aerosphere, Symbicort | $61,560 | $204,037224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 571 pulmonary disease providers in Ohio.
Other pulmonary disease in Lima
- Jason StieneckerLima$397K
- Sarat KuchipudiLima$23K
- Joseph KhabbazaAkron$655K
- Robert BaughmanCincinnati$640K
- Kristin HighlandCleveland$551K
- Bruce CorserCincinnati$502K
- Mohammad SheattCincinnati$389K
- Mohammad KhanAkron$388K
- Thomas YungerDayton$353K
- Joseph CiceniaCleveland$350K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.